📣 VC round data is live. Check it out!

Steris Valuation Multiples

Discover Steris' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Terumo, Sartorius, Straumann Group, West Pharma and more.

Steris Overview

About Steris

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.


Founded

2014

HQ

United States

Employees

17.8K

Website

steris.com

Financials (LTM)

Revenue: $6B
EBITDA: $2B

EV

$22B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Steris Financials

Steris reported last 12-month revenue of $6B and EBITDA of $2B.

In the same LTM period, Steris generated $3B in gross profit, $2B in EBITDA, and $837M in net income.

Revenue (LTM)


Steris P&L

In the most recent fiscal year, Steris reported revenue of $6B and EBITDA of $2B.

Steris is profitable as of last fiscal year, with gross margin of 44%, EBITDA margin of 28%, and net margin of 13%.

See analyst estimates for Steris
LTMLast FY202320242025202620272028
Revenue$6B$6B$5B$5B$6B
Gross Profit$3B$3B$2B$2B$3B
Gross Margin44%44%43%44%44%
EBITDA$2B$2B$1B$1B$2B
EBITDA Margin28%28%25%26%26%
EBIT Margin23%23%16%17%18%
Net Profit$837M$782M$310M$556M$740M
Net Margin14%13%6%10%13%
Net Debt-$1B---

Financial data powered by Morningstar, Inc.

Steris Stock Performance

Steris has current market cap of $20B, and enterprise value of $22B.

Market Cap Evolution


Steris' stock price is $209.76.

Steris share price decreased by 1.4% in the last 30 days, and by 12.7% in the last year.

Steris has an EPS (earnings per share) of $8.02.

See more trading valuation data for Steris
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$22B$20B-0.6%-1.4%-5.1%-12.7%$8.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Steris Valuation Multiples

Steris trades at 3.7x EV/Revenue multiple, and 12.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Steris

EV / Revenue (LTM)


Steris Financial Valuation Multiples

As of June 3, 2026, Steris has market cap of $20B and EV of $22B.

Steris has a P/E ratio of 24.5x.

LTMLast FY202320242025202620272028
EV/Revenue3.7x3.7x4.3x4.1x3.8x
EV/EBITDA12.9x13.1x17.5x16.1x14.4x
EV/EBIT15.7x16.0x26.4x23.6x20.7x
EV/Gross Profit8.3x8.4x10.0x9.4x8.6x
P/E24.5x26.2x65.9x36.9x27.7x
EV/FCF22.5x22.5x39.6x30.0x23.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Steris Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Steris Margins & Growth Rates

Steris grew revenue by 7% and EBITDA by 8% in the last fiscal year.

In the most recent fiscal year, Steris reported gross margin of 44%, EBITDA margin of 28%, and net margin of 13%.

See estimated margins and future growth rates for Steris

Steris Margins

Last FY202420252026202720282029
Gross Margin44%44%44%44%
EBITDA Margin28%26%26%28%
EBIT Margin23%17%18%23%
Net Margin13%10%13%16%
FCF Margin17%14%16%16%

Steris Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%6%8%8%
Gross Profit Growth7%7%9%8%
EBITDA Growth8%9%12%15%
EBIT Growth10%12%14%32%
Net Profit Growth40%79%33%37%
FCF Growth-32%25%5%

Data powered by FactSet, Inc. and Morningstar, Inc.

Steris Operational KPIs

Steris' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Steris' Rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Steris' Rule of X is 47% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Steris
LTMLast FY202320242025202620272028
Rule of 4035%36%---
Bessemer Rule of X46%47%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.1M---
R&D Expenses to Revenue2%2%2%2%2%
Opex to Revenue-26%27%26%26%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Steris Competitors

Steris competitors include Terumo, Sartorius, Straumann Group, West Pharma, Fresenius, Mettler Toledo, Halma, Hologic, Illumina and Zimmer Biomet.

Most Steris public comparables operate across Medical Devices, Medical Supplies, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Terumo3.3x3.0x13.9x12.2x
Sartorius6.4x6.3x20.8x20.4x
Straumann Group5.6x5.6x18.5x18.3x
West Pharma7.1x6.9x27.9x26.0x
Fresenius1.2x1.2x7.4x7.4x
Mettler Toledo6.4x6.3x20.6x20.1x
Halma8.2x7.0x33.5x28.6x
Hologic----

This data is available for Pro users. Sign up to see all Steris competitors and their valuation data.

Start Free Trial

Acquisitions by Steris

Steris has acquired 6 companies to date.

Last acquisition by Steris was on January 12th 2021. Steris acquired Cantel Medical for $5B (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Steris

Cantel Medical
Key Surgical
Medisafe Holdings
Synergy Health
Description
Cantel Medical is a global provider of infection prevention products for healthcare, including endoscope reprocessing systems, water purification for dialysis, and dental infection control devices. Acquired by STERIS in 2019, the New Jersey-headquartered firm supplies single-use medical devices and consumables to hospitals, endoscopy centers, and dialysis clinics worldwide, emphasizing sterile processing and compliance standards.
-
Medisafe Holdings is a UK-based manufacturer of medical washers and decontamination equipment. It specializes in research, development, and production of washer-disinfectors for healthcare settings. Acquired by Steris plc, its products integrate with Steris's healthcare segment, providing endoscope reprocessing and instrument cleaning solutions for hospitals across Europe.
-
HQ CountryUnited StatesUnited StatesUnited KingdomUnited Kingdom
HQ City
Utica, NY
Minneapolis, MN
Hereford
Wilpshire
Deal Date12 Jan 20216 Oct 202025 Jul 201613 Oct 2014
Valuation$5B$850M$34M$2B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Steris acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Steris

When was Steris founded?Steris was founded in 2014.
Where is Steris headquartered?Steris is headquartered in United States.
How many employees does Steris have?As of today, Steris has over 17K employees.
Who is the CEO of Steris?Steris' CEO is Daniel A. Carestio.
Is Steris publicly listed?Yes, Steris is a public company listed on NYSE.
What is the stock symbol of Steris?Steris trades under STE ticker.
When did Steris go public?Steris went public in 1992.
Who are competitors of Steris?Steris main competitors include Terumo, Sartorius, Straumann Group, West Pharma, Fresenius, Mettler Toledo, Halma, Hologic, Illumina, Zimmer Biomet.
What is the current market cap of Steris?Steris' current market cap is $20B.
What is the current revenue of Steris?Steris' last 12 months revenue is $6B.
What is the current revenue growth of Steris?Steris revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Steris?Current revenue multiple of Steris is 3.7x.
What is the current EBITDA of Steris?Steris' last 12 months EBITDA is $2B.
What is Steris' EBITDA margin?Steris' last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Steris?Current EBITDA multiple of Steris is 12.9x.
What is the current FCF of Steris?Steris' last 12 months FCF is $983M.
What is Steris' FCF margin?Steris' last 12 months FCF margin is 16%.
What is the current EV/FCF multiple of Steris?Current FCF multiple of Steris is 22.5x.
How many companies Steris has acquired to date?As of June 2026, Steris has acquired 6 companies.
What was the largest acquisition by Steris?$5B acquisition of Cantel Medical on 12th January 2021 was the largest M&A Steris has done to date.
What companies Steris acquired?Steris acquired Cantel Medical, Synergy Health, Key Surgical, Integrated Medical Systems, Medisafe Holdings, and Life Systems.
In how many companies Steris has invested to date?Steris hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Steris

Lists including Steris

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial